The evaluation of pirfenidone effects on prevention and treatment of pulmonary fibrosis and acute respiratory distress syndrome caused by COVID-19

Kermanshah University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新: 2020年5月18日

试验速览

暂无简介。

•Confirmed cases of New coronavirus infection or COVID-19 who are 18 years and older;
•Not more than 14 days from the onset of symptoms
•Bilateral lung involvement in imaging findings
•Moderate to severe acute respiratory distress syndrome
•Decreased PaO2 to FiO2 ratio

•AST and ALT> 3-5x ULN at visit and bilirubin> 1.5 x ULN at visit
•creatinine clearance rate calculated by Cockcroft-Gault formula at visit 1 <30 mL / min
•Confirmed previous Idiopathic pulmonary fibrosis,previous treatment with Nidanib or Pirfenidone
•Significant pulmonary hypertension (PAH)
•Cardiovascular diseases, including any of the following diseases: ? Severe hypertension within 6 months of Visit 1, uncontrollable after treatment (=160 / 100 mmHg); ? myocardial infarction within 6 months of visit 1; ? unstable angina within 6 months of visit 1
•history of severe central nervous system (CNS) events
•known trials Drug allergies
•Patients unable to follow the trial procedures
•Breastfeeding

发起方